Brief: Somalogic Says Q2 Revenue Rose 176% To About $19.7 Mln
16/08/2021 13:23
Aug 16 (Reuters) - SOMALOGIC:
* SOMALOGIC SAYS Q2 REVENUE ROSE 176% TO ABOUT $19.7 MILLION
* SOMALOGIC ANNOUNCES REGISTRATION STATEMENT DECLARED
EFFECTIVE
AND REPORTS 176% Y/Y SECOND QUARTER AND 187% FIRST HALF OF 2021
REVENUE GROWTH
Further company coverage: CMII.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Somalogic
See all newsBrief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Madryn Asset Management Demands Somalogic’S Board Address Repeated, Unprecedented Adjournments Of Tainted Special Meeting
Brief: Madryn Asset Management Says It Urges All Somalogic Shareholders To Oppose Transaction With Standard Biotools
Brief: Madryn Asset Management Urges Shareholders To Vote “Against” The Proposed Merger And Allow Somalogic To Pursue Value-Enhancing Alternatives
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders